68% of Organizations Under Attack: New Report from CoreView Reveals Microsoft 365 Security Risks
WASHINGTON — CoreView today announced the release of its new research report, 'The State of Microsoft 365 Security – 2025 Survey,' which reveals alarming insights about the challenges of managing Microsoft 365 environments. Conducted globally, the report includes insights from IT and security professionals across the US, Canada, UK, Australia, France, and Germany, highlighting crucial statistics that underscore the urgent need for enhanced security measures:
Article content
49% of IT leaders mistakenly believe that Microsoft backs up their configurations automatically, leaving them vulnerable in the event of a disaster.
51% of respondents have over 250 over privileged Entra applications with read-write permissions, posing significant security risks.
68% of organizations face cyberattacks daily, highlighting the critical need for robust security protocols.
Despite the fact that 99.9% of account compromises occur in accounts lacking Multi-Factor Authentication (MFA), only 41% of organizations have implemented MFA effectively.
Article content
'In a landscape where 49% of IT leaders mistakenly believe their configurations are backed up by Microsoft, and 68% of organizations are facing constant cyber threats, it's crucial for businesses to reevaluate their security strategies,' says Simon Azzopardi, an expert in cloud security. 'This report serves as a wake-up call, urging organizations to invest in comprehensive security tools and practices.'
Article content
The report outlines six major pain points that organizations face when securing their Microsoft 365 systems, offering insights into areas such as tenant management, excessive application privileges, and the misconceptions surrounding data backup processes.
Key Findings:
Article content
Tenant Dilemma: Most organizations operate multiple tenants due to complexities related to data security and operational efficiency.
Privilege Risks: As the number of applications continues to grow, the associated security risks escalate, requiring tighter governance over permissions.
Backup Misconceptions: Many organizations are underprepared, assuming backup solutions are in place when, in reality, they are vulnerable to data loss during an incident.
Configuration Tampering: The necessity of detecting configuration changes is emphasized, as many organizations remain unaware of ongoing tampering risks.
Article content
Availability of the Report
Article content
The 'State of Microsoft 365 Security – 2025 Survey' is now available for download from CoreView's website. It is an essential resource for IT leaders and decision-makers tasked with safeguarding their organizations in a rapidly evolving threat landscape.
Article content
About CoreView
Article content
CoreView empowers organizations to secure, manage, and optimize complex Microsoft 365 environments, including some of the world's largest tenants. The platform provides enterprise-grade cyber resilience tailored for diverse needs, whether managing multiple tenants or consolidating into a single environment. CoreView simplifies administration, strengthens security, and identifies opportunities to reduce costs across your Microsoft 365 landscape.
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
8 minutes ago
- CTV News
Trump pressures 17 pharma CEOs to cut U.S. drug prices
Pills spill in an arrangement photo of prescription Oxycodone in New York. (AP Photo/Mark Lennihan, File) U.S. President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about two per cent each, while the NYSE Arca Pharmaceutical Index fell three per cent on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until Sept. 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said. Jeff Mason, Nandita Bose, Patrick Wingrove, Reuters
Globe and Mail
8 minutes ago
- Globe and Mail
Why Novo Nordisk Stock Crumbled Again Today
Key Points An analyst downgraded the stock. He now feels it is only a hold as opposed to a buy. 10 stocks we like better than Novo Nordisk › The hits just kept coming for beleaguered Ozempic and Wegovy maker Novo Nordisk (NYSE: NVO) on Thursday. The company, which has been slammed with investor sell-offs since cutting its guidance on Tuesday, fell by almost 6% as yet another analyst weighed in with a bearish take on its prospects. The S&P 500 index, meanwhile, traded down only slightly. A downgrade to hold That pundit was HSBC 's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) per share from the preceding 680 krone ($104.81). According to reports, Kumar particularly expressed concern about compounded weight-loss drugs, a form of competition that has affected Novo Nordisk's otherwise lively Ozempic and Wegovy sales. The analyst wrote that although the U.S. Food and Drug Administration (FDA) has banned compounding, rivals continue to sell such drugs illegally. Kumar does not believe this situation will change much in the near future, so he believes current estimates for total GLP-1 drug sales might be overestimated. Reasons to be cheerful The HSBC pundit certainly raises valid concerns and questions, although the ultimate effect of the compounding ban on Novo Nordisk will depend on how effectively it's enforced; perhaps, in contrast to Kumar's view, the offending parties will be caught and punished. I wouldn't be as down on the Danish company as the analyst. That hot competition only proves how popular Wegovy and its ilk are at the moment, and in a vast country like the U.S. that has a clear problem with obesity, that should continue to motor its fundamentals higher. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
8 minutes ago
- Globe and Mail
Stock Market Today: Applied Digital Soars 31% on CoreWeave Deal and Earnings Surprise
Applied Digital (NASDAQ: APLD) stock skyrocketed 31% on Thursday to close at $13.14, making it one of the day's top-performing small-cap tech stocks. The rally was likely related to the company's stronger-than-expected fiscal Q4 earnings report (released Wednesday after market close) and a major expansion of its long-term lease agreement with AI hyperscaler CoreWeave (NASDAQ: CRWV). The company saw trading volume more than 2.5 times its recent average, indicating heavy institutional interest. While Applied Digital remains about 17% below its 52-week high of $15.42, the stock decisively broke above recent resistance levels and is now up sharply year-to-date. Broader markets traded softly, the S&P 500 declined 0.4%, while the Nasdaq Composite was effectively flat (down 0.03%) after briefly hitting an all-time intraday high. Still, Applied Digital significantly outperformed key peers. DigitalOcean (NYSE: DOCN) was little changed at +0.2%, while Super Micro Computer (NASDAQ: SMCI) slid 2.9%. In fiscal Q4, Applied reported $38 million in revenue, up 41% year over year, and an adjusted EPS loss of $0.03, easily beating analyst expectations. Most notably, the company announced that CoreWeave exercised a 150-megawatt (MW) lease option, boosting total contracted capacity to 400 MW and unlocking up to $11 billion in potential revenue over the next 15 years. CEO Wes Cummins emphasized acceleration at the company's Polaris Forge 1 campus and reiterated long-term plans to generate $1 billion in annual NOI within 3–5 years, supported by demand from hyperscale cloud customers. Should you invest $1,000 in Applied Digital right now? Before you buy stock in Applied Digital, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Applied Digital wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Daily Stock News has no position in any of the stocks mentioned. This article was generated with GPT-4o, OpenAI's large-scale language-generation model and has been reviewed by The Motley Fool's AI quality control systems.
